265 related articles for article (PubMed ID: 11888344)
21. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.
Parnetti L; Amici S; Lanari A; Romani C; Antognelli C; Andreasen N; Minthon L; Davidsson P; Pottel H; Blennow K; Gallai V
Neurol Sci; 2002 Sep; 23 Suppl 2():S95-6. PubMed ID: 12548360
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of human cholinesterases by drugs used to treat Alzheimer disease.
Darvesh S; Walsh R; Kumar R; Caines A; Roberts S; Magee D; Rockwood K; Martin E
Alzheimer Dis Assoc Disord; 2003; 17(2):117-26. PubMed ID: 12794390
[TBL] [Abstract][Full Text] [Related]
23. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
[TBL] [Abstract][Full Text] [Related]
24. [Cholinesterases and their importance in the etiology, diagnosis and therapy of Alzheimer's disease].
Patocka J; Strunecká A; Rípová D
Cesk Fysiol; 2001 Feb; 50(1):4-10. PubMed ID: 11268561
[TBL] [Abstract][Full Text] [Related]
25. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months.
Darreh-Shori T; Almkvist O; Guan ZZ; Garlind A; Strandberg B; Svensson AL; Soreq H; Hellström-Lindahl E; Nordberg A
Neurology; 2002 Aug; 59(4):563-72. PubMed ID: 12196650
[TBL] [Abstract][Full Text] [Related]
26. Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles.
Eskander MF; Nagykery NG; Leung EY; Khelghati B; Geula C
Brain Res; 2005 Oct; 1060(1-2):144-52. PubMed ID: 16212945
[TBL] [Abstract][Full Text] [Related]
27. The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis.
Bullock R
Int J Clin Pract; 2002 Apr; 56(3):206-14. PubMed ID: 12018828
[TBL] [Abstract][Full Text] [Related]
28. A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.
Nordberg A; Ballard C; Bullock R; Darreh-Shori T; Somogyi M
Prim Care Companion CNS Disord; 2013; 15(2):. PubMed ID: 23930233
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and molecular docking studies of 5-trifluoromethoxy-2-indolinones as cholinesterase dual inhibitors.
Soylu-Eter Ö; Özsoy N; Karalı N
Future Med Chem; 2024 Apr; 16(7):623-645. PubMed ID: 38470247
[No Abstract] [Full Text] [Related]
30. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.
Pacheco G; Palacios-Esquivel R; Moss DE
J Pharmacol Exp Ther; 1995 Aug; 274(2):767-70. PubMed ID: 7636741
[TBL] [Abstract][Full Text] [Related]
31. Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis.
Kamal MA; Qu X; Yu QS; Tweedie D; Holloway HW; Li Y; Tan Y; Greig NH
J Neural Transm (Vienna); 2008 Jun; 115(6):889-98. PubMed ID: 18235987
[TBL] [Abstract][Full Text] [Related]
32. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development--a study of molecular forms.
Arendt T; Brückner MK; Lange M; Bigl V
Neurochem Int; 1992 Oct; 21(3):381-96. PubMed ID: 1303164
[TBL] [Abstract][Full Text] [Related]
33. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R
Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
[TBL] [Abstract][Full Text] [Related]
34. Cholinesterases: roles in the brain during health and disease.
Ballard CG; Greig NH; Guillozet-Bongaarts AL; Enz A; Darvesh S
Curr Alzheimer Res; 2005 Jul; 2(3):307-18. PubMed ID: 15974896
[TBL] [Abstract][Full Text] [Related]
35. Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo.
Darreh-Shori T; Forsberg A; Modiri N; Andreasen N; Blennow K; Kamil C; Ahmed H; Almkvist O; Långström B; Nordberg A
Neurobiol Aging; 2011 Dec; 32(12):2320.e15-32. PubMed ID: 20538374
[TBL] [Abstract][Full Text] [Related]
36. Recent approaches to novel anti-Alzheimer therapy.
Carreiras MC; Marco JL
Curr Pharm Des; 2004; 10(25):3167-75. PubMed ID: 15544506
[TBL] [Abstract][Full Text] [Related]
37. Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer's Disease: Nexus of Cholinergic and Nerve Growth Factor Dysfunction.
Moss DE; Perez RG
Curr Alzheimer Res; 2021; 18(13):1010-1022. PubMed ID: 34911424
[TBL] [Abstract][Full Text] [Related]
38. Protease inhibitors and indolamines selectively inhibit cholinesterases in the histopathologic structures of Alzheimer's disease.
Wright CI; Geula C; Mesulam MM
Ann N Y Acad Sci; 1993 Sep; 695():65-8. PubMed ID: 8239315
[TBL] [Abstract][Full Text] [Related]
39. Cholinesterases and the fine line between poison and remedy.
Pope CN; Brimijoin S
Biochem Pharmacol; 2018 Jul; 153():205-216. PubMed ID: 29409903
[TBL] [Abstract][Full Text] [Related]
40. Glucocorticoids differentially control synthesis of acetylcholinesterase and butyrylcholinesterase in rat liver and brain.
Weber U; Brank M; Grubic Z
Chem Biol Interact; 1999 May; 119-120():341-7. PubMed ID: 10421470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
